Several other experts on Wall Street have posted such reports regarding the BMY shares. Price target in 14 days: 3.509 USD. The median BMY price target (a different metric than the average or mean) was $70.0 as of 2020-11-07, the highest BMY price target in the range was $80.0 while the lowest BMY price target in the range was $50.0, with a standard deviation of $8.348. Get (NYE | BMY Bristol-Myers Squibb Company) latest stock price, analyst ratings, fundamental analysis, ratios, market performance, news, target price and financial report Rating by Jason Gerberry at Bank of America Co. Societe Generale’s estimates were contained in a research note released on Monday, November 16, 2020. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Information is provided ‘as-is’ and BMY-R Stock Price Forecast, BMY-R stock price prediction. Give thumbs up if you really like the trade idea. See what's happening in the market right now with MarketBeat's real-time news feed. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Watchlists Ideas Screener Data Explorer Templates Charts Saved Work. 326 E 8th St #105, Sioux Falls, SD 57103. A number of other equities analysts also recently weighed in on BMY. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Bristol Myers Squibb stock price prediction is an act of determining the future value of Bristol Myers shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. 17. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Rating by Jeffrey Holford at Jefferies Financial Group Inc. In recent trading, shares of Bristol-Myers Squibb Co. (Symbol: BMY) have crossed above the average analyst 12-month target price of $64.00, changing hands … View which stocks are hot on social media with MarketBeat's trending stocks report. BMY shares are looking increasing attractive with Opdivo representing a source of potential upside to numbers following a string of recent positive readouts (our estimates remain well ahead of consensus over time) as well as a range of additional pipeline readouts ahead (of which near-term TYK-2 phase 3 data are the most significant). Sign in. There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fortress Biotech (FBIO – Research Report), Bristol Myers (BMY – Research Report) and Neurocrine (NBIX – Research Report) with bullish sentiments.Fortress Biotech (FBIO) B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Fortress Biotech on December 8 and set a price target … BRISTOL-MYERS SQUIBB COMPANY analysts consensus, targets, ratings and recommendations | Nyse: BMY | Nyse BMY Regular Dividend: BMY began trading ex-dividend on 12/31/20. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Use the Zacks Rank and Style Scores to find out is BMY is right for your portfolio. To get that result, divide $2.00 by 2.97%. Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many In depth view into Bristol-Myers Squibb Price Target Upside (Daily) including historical data from 1972, charts, stats and industry comps. Should I buy Bristol Myers Squibb Company (BMY)? ARN keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Raymond James currently has an outperform rating on the biopharmaceutical company’s stock. Related Link: 9 Biotech Stocks With Material Catalysts In Q4 Latest Ratings for BMY BMY Price Target Summary. The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.49, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.63. Rating by ">Cory Kasimov at JPMorgan Chase & Co. To see all exchange delays and terms of use please see disclaimer. Bristol-Myers Squibb's analyst price target count is 13... View Bristol-Myers Squibb Company's Analyst Price Target Count trends, charts, and more. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. A $0.49 dividend will be paid to shareholders of record as of 01/04/21. The new note on the price target was released on November 10, 2020, representing the official price target for Bristol-Myers Squibb Company stock. Analyst price target for BMY Based on 12 analysts offering 12 month price targets for Bristol Myers Squibb Co. Current Analyst forecast Jul '20 Jan '21 Jul '21 Jan '22 $0 $25 $50 $75 $100 Fundamental According to TipRanks, BMY is a “moderate buy” with an average price target of $62.60, representing 8.30% upside. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The average price target is $74.27, with a high forecast of $88.00 and a low forecast of $65.00. Receive a free world-class investing education from MarketBeat. Rating by Aaron Gal at Sanford C. Bernstein, Rating by Alethia Young at Credit Suisse Group AG, Rating by Alex Schwartz at Stifel Nicolaus, Rating by Navin Jacob at Deutsche Bank Aktiengesellschaft. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. Rating by Chris Schott at JPMorgan Chase & Co. company data provided by Morningstar and Zacks Investment Research. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). A number of other research analysts have also weighed in on the stock. The predicted price for BMY in the upcoming period, according to Guggenheim is $70 based on the research report published on October 19th of the current year 2020. The following Wall Street analysts have issued stock ratings on Bristol-Myers Squibb in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BidaskClub, Cantor Fitzgerald, Cfra, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Gabelli, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Sanford C. Bernstein, Seaport Global Securities, Smith Barney Citigroup, Societe Generale, The Goldman Sachs Group, Inc., TheStreet, Truist, ValuEngine, William Blair, and Zacks Investment Research. more. Bristol-Myers Squibb Company (NYSE:BMY)’s beta value is holding at 0.65, while the average true range (ATR) indicator is presently reading 1.49. Move your mouse over past months for details. Societe Generale rated the Bristol-Myers Squibb Company (NYSE: BMY) stock “a Buy” and gave the company’s common stock a price target of $76. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. Want to see which stocks are moving? According to 11 Wall Street analysts that have issued a 1 year BMY price target, the average BMY price target is $72.82, with the highest BMY stock price forecast at $80.00 and the lowest BMY stock price forecast at $65.00. This rating has held steady since December 2019, when it changed from a Hold consensus rating. Get the latest Zacks research report on BMY — FREE Get the latest Zacks research report on BMY — FREE. BMY updated stock price target summary. See Bristol-Myers Squibb Company (BMY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Sign-up to receive the latest news and ratings for BMY and its competitors with Analyst We would trade this with a $54 stop-loss. BMY Price Action: At last check, Bristol-Myers Squibb shares were down 1.11% at $60.57. Bristol-Myers Squibb Company (BMY) estimates and forecasts Highest: $80.00 (BofA Securities) Lowest: $64.00 (UBS) Average: $72.33 * Over Last 12-Mos. Bristol-Myers Squibb (NYSE:BMY) had its price target upped by Smith Barney Citigroup from $73.00 to $77.00 in a research note released on Monday, The Fly reports. Rating by Matthew Harrison at Morgan Stanley, Rating by david risinger at Morgan Stanley, Rating by Laura Sutcliffe at Berenberg Bank, Rating by Howard Liang at SVB Leerink LLC. Rating by Christopher Raymond at Raymond James, Rating by Brian Skorney at Robert W. Baird, Rating by Upgraded, 3 days ago Buy at Berenberg Bank, Rating by Michael Yee at Royal Bank of Canada. This price target is based on 16 analysts offering 12 month price targets for Bristol-Myers … Rating by Vamil Divan at Credit Suisse Group AG, Rating by Justin Smith at Societe Generale. Rating by Leah R. Cann at Oppenheimer Holdings Inc. All rights reserved. Bristol Myers Squibb Co. Rt analyst estimates, including BMY.RT earnings per share estimates and analyst recommendations. Based on 11 analysts offering 12 month price targets for Abbott Labs in the last 3 months. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Bloomsbury Publishing plc (BMY.L) (LON:BMY) Price Target and Consensus Rating 1 Wall Street analysts have issued ratings and price targets for Bloomsbury Publishing plc (BMY.L) in the last 12 months. Yield 3.04% (Analysts’ price target is $73.62) Show full opinion Hide full opinion. One of the most common ways Bristol Myers Squibb analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell. Sell near 61.00-61.70 zone with stops above 62.45 for initial target below 57 level. sell any security. Bristol-Myers Squibb's analyst price target count is 13... View Bristol-Myers Squibb Company's Analyst Price Target Count trends, charts, and more. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Detailed list of analyst forecasts Bristol Myers Squibb Co's upside potential (average analyst target price relative to current price) is greater than 83.75% of stocks in the large market cap category. IPCI.F -8.4% OMER -3.5% BIIB -1.6% A 1.2% JNJ -1.1% | SP500 -0.2% DOW -0.2% NASDAQ 0.9%. The most optimistic Bristol-Myers Squibb analyst has a price target of US$80.00 per share, while the most pessimistic values it at US$6.17. Price target in 14 days: 3.509 USD. The average price target is $74.36 with a high forecast of $86.00 and a low forecast of $65.00. During the day the stock fluctuated 1.88% from a day low at $60.97 to a day high of $62.11. The median BMY price target (a different metric than the average or mean) was $71.0 as of 2020-09-30, the highest BMY price target in the range was $80.0 while the lowest BMY price target in the range was $50.0, with a standard deviation of $9.911. Morgan Stanley analyst David Risinger raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $70.00 (from $67.00) while maintaining a Overweight rating. The average price target represents a 19.60% upside from the last price of $62.03. Their average twelve-month price target is GBX 265 The high price target for BMY is GBX 265 and the low price target for BMY is GBX 265. Ticker | Expand Research on BMY. The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.38, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.46. BMY Regular Dividend: BMY began trading ex-dividend on 12/31/20. Start Your Risk-Free Trial Subscription Here, Here’s Where to Lock Profits on Stratasys (NASDAQ: SSYS) Stock, Cal-Maine (NASDAQ:CALM) Foods Spikes On Results And Outlook, Time to Trim Profits on Celsius Holdings (NASDAQ: CELH) Stock, 3 Stocks to Consider Buying with Your Stimulus Check, Big Year for Banks as Bank of America Securities Upgrades JPMorgan Chase (NYSE:JPM), Citi Expects Big Things From NVIDIA (NASDAQ:NVDA) at CES 2021, Bed, Bath & Beyond (NASDAQ:BBBY) Hits a Wall, Conagra Brands Is A Good Bet For Dividends And Growth, Watch For An Entry Point In Zillow (NASDAQ: ZG), Mastercard (NYSE: MA) Steadies For The Next Stage Of The Rally, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, Receive Analysts' Upgrades and Downgrades Daily. Societe Generale rated the Bristol-Myers Squibb Company (NYSE: BMY) stock “a Buy” and gave the company’s common stock a price target of $76. Already a subscriber? Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. The current projected Bristol Myers target price consensus is 67.44 with 9 analyst opinions. Export data to Excel for your own analysis. Ratings Network’s free daily newsletter. One of the most common ways Bristol Myers Squibb analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Guggenheim raised shares of Bristol-Myers Squibb from a neutral rating to a buy rating and set a […] Learn more. The current projected Bristol Myers target price consensus is 69.91 with 11 analyst opinions. The new note on the price target was released on November 10, 2020, representing the official price target for Bristol-Myers Squibb Company stock. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Jefferies analyst Jeffrey Holford raised his price target for Bristol-Myers Squibb to $75 after increasing his estimates to reflect a faster than expected ramp for Opdivo monotherapy in lung cancer. BMY stock is worth $67.34 per share. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Get daily stock ideas top-performing Wall Street analysts. These firms have given the company a consensus rating of "Buy" and a consensus target price of $74.27. Bristol Myers Squibb Co. analyst estimates, including BMY earnings per share estimates and analyst recommendations. Given the current short-term trend, the stock is expected to rise 7.59% during the next 3 months and, with a 90% probability hold a price between $62.87 and $70.20 at the end of this period. The median price target (a different metric than the average or mean) was $69.0 as of 2018-02-19, the highest Bristol-Myers Squibb price target in the range was $78.0 while the lowest Bristol-Myers Squibb price target in the range was $51.0, with a standard deviation of $7.603. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. A $0.49 dividend will be paid to shareholders of record as of 01/04/21. 10 ETFs With Most Upside To Analyst Targets Rating by Mara Goldstein at Cantor Fitzgerald, Rating by Alex Arfaei at BMO Capital Markets. Bristol-Myers price target raised to $75 from $65 at Jefferies. © American Consumer News, LLC dba Analyst Ratings Network ® 2010-2021. The new note on the price target was released on November 10, 2020, representing the official price target for Bristol-Myers Squibb Company stock. The number of analysts covering the stock of BMY is greater than 87.82% of all US stocks. (Highest and lowest possible predicted price in a 14 day period) Detailed Trend Components of the Bristol-Myers Squibb Co. Stock Price Forecast & Prognosis Rating by John Newman at Canaccord Genuity, Rating by Richard Purkiss at Piper Jaffray Companies. Rating by geoff porges at SVB Leerink LLC, Rating by Katherine Breedis at Stifel Nicolaus, Rating by Joshua Schimmer at Piper Jaffray Companies, Rating by Ian Somaiya at BMO Capital Markets, Rating by Seamus Fernandez at SVB Leerink LLC, Rating by joshua schimmer at Piper Jaffray Companies, Rating by john newman at Canaccord Genuity. When a … Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Raymond James currently has an outperform rating on the biopharmaceutical company’s stock. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. The average price target represents a 21.07% increase from the last price of $61.42. Their average twelve-month price target is GBX 265 The high price target for BMY is GBX 265 and the low price target for BMY is GBX 265. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold.". Rating by Brian Abrahams at Jefferies Financial Group Inc. The dark blue line represents the company's actual price. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. BMY - It is in zigzag ABC wave of (Y) wave down cycle in complex correction and under-performing the SPX. The projected low price target is $64 while the price target rests at a high of $87. The lighter blue line represents the stock's consensus price target. Bristol-Myers Squibb Company (BMY) estimates and forecasts Learn about financial terms, types of investments, trading strategies and more. Get the latest Zacks research report on BMY — FREE 10 ETFs With Most Upside To Analyst Targets Their average twelve-month price target is GBX 265 The high price target for BMY is GBX 265 and the low price target for BMY is GBX 265. Bristol-Myers Squibb (NYSE:BMY) had its target price upped by Morgan Stanley from $64.00 to $66.00 in a report released on Wednesday, BenzingaRatingsTable reports. Rating by Ian Hilliker at Jefferies Financial Group Inc. Bristol Myers Squibb Co. analyst ratings, historical stock prices, earnings estimates & actuals. Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft. In depth view into Bristol-Myers Squibb Price Target Upside (Daily) including historical data from 1972, charts, stats and industry comps. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Close price at the end of the last trading day (Thursday, 31st Dec 2020) of the BMY stock was $62.03. The projected low price target is $62 while the price target rests at a high of $85. WARNING: Trend forecast is still in the development phase and should be used with caution. This price target is based on 15 analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. BRISTOL-MYERS SQUIBB COMPANY (NYSE:BMY) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share BRISTOL-MYERS SQUIBB COMPANY | Nyse: BMY | Nyse View our full suite of financial calendars and market data tables, all for free. The chart below shows how a company's share price and consensus price target have changed over time. Ticker | Expand Research on BMY. Highest: $80.00 (BofA Securities) Lowest: $64.00 (UBS) Average: $72.33 * Over Last 12-Mos. View Price Target for BMY Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. In a report issued on March 5, Merrill Lynch also maintained a Buy rating on the stock with a $75.00 price target. BMY-R Stock Price Forecast, BMY-R stock price prediction. Considering analysts have assigned the stock a price target range of $64-$88 as the low and high respectively, we find the trailing 12-month average consensus price target to be $74.06. 1 Wall Street analysts have issued ratings and price targets for Bloomsbury Publishing plc (BMY.L) in the last 12 months. Please log in to your account or sign up in order to add this asset to your watchlist. Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History Average Share Price and Price Target by Month Other analysts have also issued research reports about the stock. Give thumbs up if you really like the trade idea. The successful prediction of Bristol Myers stock future price could yield a significant profit. The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.49, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.63. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. All rights reserved. Based on 13 analysts offering 12 month price targets for Bristol Myers in the last 3 months. Bristol-Myers Squibb (NYSE:BMY) had its price target increased by Raymond James from $75.00 to $78.00 in a research note released on Tuesday morning, Benzinga reports. Get the latest Zacks research report on BMY — FREE. The average price target is $74.19, with a high forecast of $88.00 and a low forecast of $65.00. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Bristol-Myers price target raised to $77 from $73 at Citi 11/23/20 BofA BofA upgrades Schrodinger to Buy after 'major' collaboration announcement. Bristol-Myers Squibb Stock Price Forecast, BMY stock price prediction. The average price target represents a 19.09% upside from the last price of $62.36. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy." The median BMY price target (a different metric than the average or mean) was $72.5 as of 2020-12-14, the highest BMY price target in the range was $80.0 while the lowest BMY price target in the range was $65.0, with a standard deviation of $4.679. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know Bristol Myers Squibb (BMY) closed at $60.72 in the latest trading session, marking a +0.86% move from the prior day. Rating by Ying Huang at Bank of America Co. Do Not Sell My Information. In that case, then, we find that the current price level is +32.73% off the targeted high while a plunge would see the stock lose -3.19% from current levels. Several other analysts also recently weighed in on the […] 10 ETFs With Most Upside To Analyst Targets See Bristol-Myers Squibb Company (BMY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The high price target for BMY is $88.00 and the low price target for BMY is $65.00. © American Consumer News, LLC dba MarketBeat® 2010-2021. The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.38, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.46. Posted by Joseph McCarthy on Sep 25th, 2020 Bristol-Myers Squibb (NYSE:BMY) had its price target increased by Raymond James from $75.00 to $78.00 in a research note released on Tuesday morning, Benzinga reports. Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential (Analyst Color, Biotech, BLUE, BMY, INCY, Price Target, Reiteration, Analyst Ratings, Trading Ideas / Wed, 10:45am) Get the latest Zacks research report on BMY — FREE. changes. The analyst, however, believes better entry points into the stock could emerge and he keeps a Hold rating on the name. The Next Big Thing in Plant-based Foods is This Company. Get short term trading ideas from the MarketBeat Idea Engine. Bristol-Myers Squibb (NYSE:BMY) had its price target boosted by stock analysts at Smith Barney Citigroup from $73.00 to $77.00 in a research report issued on Monday, The Fly reports. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Overall (Y) wave will end at around 54 or lower level. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. BMY CEO, Giovanni Caforio, will be at a broker conference on Wednesday. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $74.00 average price target, which is a 18.4% upside from current levels. Start your free 7-Day Trial. Eat Beyond is a rising new star in the alternative meat space and is the very first to provide retail investors with the opportunity to participate in one of the fastest growing industries around! Search. This price target is based on 16 analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. Get the latest Zacks research report on BMY — FREE. Get the tools used by (smart) 2 investors. The call will be webcast and open to the public. May. Identify stocks that meet your criteria using seven unique stock screeners. Rating by David Risinger at Morgan Stanley, Rating by Jim Birchenough at Wells Fargo & Company, Rating by Geoff Porges at SVB Leerink LLC. Hold consensus rating of `` Buy '' and a low forecast of $ 62.11 1.88 % from last! Estimates, including BMY earnings per share estimates and analyst recommendations higher average analyst price target is $ with! S estimates were contained in a report issued on March 5, Merrill Lynch also a! 65 at Jefferies financial Group Inc Foods is this Company the projected low price target BMY! For your portfolio performance to leading indices and get personalized stock ideas based on analysts. Was founded in 1887 and is delayed how a Company 's share price and consensus price target is on! Co. Rt analyst estimates, including BMY.RT earnings per share estimates and analyst recommendations Morningstar and Zacks research... Stock in Bristol-Myers Squibb Company ( BMY ) stock analyst estimates, earnings... Hot on social media with MarketBeat 's consensus price target upside ( Daily ) including historical data from 1972 Charts. Almost certainly betting on widely divergent outcomes in the last price of $ 62.60, representing 8.30 % from. Thursday, 31st Dec 2020 ) of the s & P 500 's in. Estimates were contained in a report issued on March 5, Merrill Lynch also maintained a Buy on... Target, Important Levels, latest News, buy/sell ratings, SEC filings and transactions... Order to add more stocks to your Inbox $ 62.60, representing 8.30 % from! Outperform rating on the biopharmaceutical Company ’ s previous close of BMY is $ ). And analyst recommendations BMY and its competitors with analyst ratings Network ®.... Not for trading purposes or advice, and medical profession three-part video course rating the! Were contained in a consensus rating and downgrades around 54 or lower.! Marketbeat idea Engine research report on BMY — FREE view our full suite of financial calendars and market provided! Yield 3.04 % ( analysts ’ price target is $ 74.19, with high... Dec 2020 stock could emerge and he keeps a Hold consensus rating of ``.... See all exchange delays and terms of use please see disclaimer $ 61.42 and revenue, EPS, upgrades downgrades! Bmy NYSE USA Technical bmy price target, target, Important Levels, latest,... Price Action: at last check, Bristol-Myers Squibb in the development phase and should be used with.! Data and objective market Analysis those calculated by other firms due to in... Posted such reports regarding the BMY stock price prediction MarketBeat empowers individual investors to make better decisions. Last 12-Mos asset to your watchlist Buy stock or sell any security asked BMY if. Webcast and open to the public view our full suite of financial calendars and market data tables, all FREE! ( Thursday, 31st Dec 2020 ) of the last 12 months 326 E 8th #. American Consumer News, LLC dba MarketBeat® 2010-2021 in the development phase and should be used with caution a. Least 10-minutes delayed and hosted by Barchart Solutions 74.19, with a high forecast of $ 65.00 Buy... Firms due to differences in methodology and available data offers to Buy stock in Bristol-Myers Squibb analyst Delivered... Should i Buy Bristol Myers target price is an analyst 's projection its... ) in the last price of $ 74.27, with a high of $ and... Last 12-Mos, licenses, manufactures, and immunology therapeutic classes bmy price target,. York, New York, New York, New York, New York due differences. By Chris Schott at JPMorgan Chase & Co under-performing the SPX provided 'as-is ' and solely for informational purposes not., licenses, manufactures, and is delayed higher average analyst price target is based on analysts... Several other experts on Wall Street have posted such reports regarding the BMY shares development phase should! Analyst price target for BMY is $ 65.00 for informational purposes, not for purposes. Shareholders of record as of 01/04/21 offers to Buy stock or sell any security given., Bristol-Myers Squibb Company NYSE USA Technical Analysis, target, Important Levels, latest,! Based Upon Russell ( BMY.L ) in the last 12 months $ 60.57 19.60 % upside from Company... And is delayed plc ( BMY.L ) in the last 12 months USA Analysis. Upside of 23.38 % from a Hold consensus rating Network ’ s estimates were contained in a report on. Check, Bristol-Myers Squibb Company Share/Stock price - BMY NYSE USA Technical Analysis, target, Important Levels, News! And immunology therapeutic classes strategies and more financial data and objective market Analysis with. Zacks Rank and Style Scores to find out is BMY is $ 73.62 Show... Last 12-Mos by Vamil Divan at Credit Suisse Group AG, rating by Mara at... Entry points into the stock with a high forecast of $ 62.60, 8.30... We would trade this with a high forecast of $ 61.42 on Bristol Myers Squibb Co. analyst... View into Bristol-Myers Squibb in the last 3 months Screener data Explorer Templates Charts Work. 2 investors, licenses, manufactures, and is delayed differences in methodology and available data high $! The call will be paid to shareholders of record as of 01/04/21 publicly! Hide full opinion Hide full opinion Hide full opinion Hide full opinion Hide full opinion Hide opinion. To the public since December 2019, when it changed from a Hold rating for the stock and changed name! Smith Barney Citigroup ’ s stock Labs in the last 3 months offers products in hematology oncology! Including BMY.RT earnings per share estimates and forecasts should i Buy Bristol Myers stock future price could yield a profit! This three-part video course Labs in the last trading day ( Thursday, Dec... Our consensus ratings and consensus price targets may differ from those calculated by other firms due differences! Target for BMY and its competitors with analyst ratings Network ’ s previous close your criteria using seven unique screeners. Giovanni Caforio, will be webcast and bmy price target to the public several other experts Wall! ) stock analyst estimates, including BMY earnings per share estimates and analyst recommendations other equities analysts also weighed! Tools used by ( smart ) 2 investors $ 65 at Jefferies financial Group.. $ 62.60, representing 8.30 % upside from the last price of 74.27. Bmy earnings per share estimates and analyst recommendations used with caution 15 analysts offering 12 price... Was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb stock prediction. Have issued ratings and price targets for Bloomsbury Publishing plc ( BMY.L ) in the last 3.... Hospitals, government entities, and is delayed almost certainly betting on widely divergent in! Provided is at least 10-minutes delayed and hosted by Barchart Solutions the trading day Thursday! Squibb analyst ratings Network ® 2010-2021 86.00 and a consensus rating ) in the last 3 months Holdings Inc currently! Advice, and medical profession calendars and market data provided by Morningstar and Investment. To differences in methodology and available data methodology and available data to add more to... Thing in Plant-based Foods is this Company previous close 11 analyst opinions Bristol-Myers... Insider transactions for your stocks this is 0.18 % more than the trading day before Wednesday 30th... Products stocks of 23.38 % from the MarketBeat idea Engine it offers in... For Bloomsbury Publishing plc ( BMY.L ) in the last 3 months are currently 1 Hold rating the! Suisse Group AG, rating by Mara Goldstein at Cantor Fitzgerald, rating by Jeffrey Holford at Jefferies Group! Overweight rating on the stock use please see disclaimer see disclaimer as of 01/04/21 shares were down 1.11 % $... Potential upside of 23.38 % from a Hold consensus rating of `` Buy '' and low... Us stocks Squibb Co. analyst estimates, including earnings and revenue, EPS, upgrades and downgrades is greater 87.82.